Close Menu

NEW YORK – Generex Biotechnology, a biopharma and diagnostics firm based in Miramar, Florida, today said that it has signed a letter of intent to acquire immunotherapy firm Kiromic.

Generex said that it intends to merge Kiromic with a newly formed entity, called NuGenerex Immuno-Oncology, that will contain the operations of both Kiromic and Generex subsidiary Antigen Express, which is developing AE37, an experimental cancer vaccine, in combination with checkpoint inhibitors for treatment of triple negative breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
27
Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments.